Literature DB >> 31069133

Microvesicles expressing adenosinergic ectoenzymes and their potential role in modulating bone marrow infiltration by neuroblastoma cells.

Fabio Morandi1, Danilo Marimpietri1, Alberto L Horenstein2,3, Maria Valeria Corrias4, Fabio Malavasi2,3,5.   

Abstract

Metastatic diffusion of Neuroblastoma (NB) cells in the bone marrow (BM) represents the most negative prognostic factors for NB patients. Multiple immune escape mechanisms are postulated as responsible. Our working hypothesis is that adenosine (ADO), an immunosuppressive molecule along with the ectoenzymatic pathways (CD39-CD73 and CD38-CD203a/PC-1-CD73) controlling its production, are involved in the dynamics of NB cells in the BM. The results indicate that ectonucleotidases are expressed by i) NB cell lines, ii) metastatic NB cells isolated from NB patients' BM, iii) microvesicles (MV) derived from both NB cell types and iv) resident BM cell populations. BM infiltration by NB cells increased CD203a/PC-1 and CD73 expression on lymphoid and myeloid cells, respectively. Expressions of ectoenzymes and GD2 (NB-associated marker) were higher on MV from NB patients' BM than in controls. Moreover, CD203a/PC-1 expression on BM-derived MV provide a basis for distinguishing NB patients with high or low BM infiltration. ADO production and consumption of related by-products were significantly higher when assessed on NB patients' MV than those from controls. MV isolated from NB patients' BM significantly downregulated in vitro T cell proliferation. Lastly, NB patients with worse prognosis are identified by a high percentage of CD38+ or CD73+ MV in the BM. In conclusion, ectonucleotidases are present and functional on NB cells, as well as in NB-infiltrated BM and in MV derived from BM. It is reasonable that MV are involved in BM infiltration by NB cells. Therefore, targeting these molecules may widen the therapeutic armamentarium for metastatic NB patients.

Entities:  

Keywords:  Neuroblastoma; adenosine; bone marrow; metastasis; microvesicles

Year:  2019        PMID: 31069133      PMCID: PMC6492972          DOI: 10.1080/2162402X.2019.1574198

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  50 in total

1.  The Cu,Zn superoxide dismutase in neuroblastoma SK-N-BE cells is exported by a microvesicles dependent pathway.

Authors:  Paolo Mondola; Giuseppina Ruggiero; Rosalba Serù; Simona Damiano; Serena Grimaldi; Corrado Garbi; Marcellino Monda; Dario Greco; Mariarosaria Santillo
Journal:  Brain Res Mol Brain Res       Date:  2003-01-31

2.  Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry.

Authors:  Riccardo Haupt; Alberto Garaventa; Claudio Gambini; Stefano Parodi; Giuliana Cangemi; Fiorina Casale; Elisabetta Viscardi; Maurizio Bianchi; Arcangelo Prete; Alessandro Jenkner; Roberto Luksch; Andrea Di Cataldo; Claudio Favre; Paolo D'Angelo; Giulio Andrea Zanazzo; Giampaolo Arcamone; Gian Carlo Izzi; Anna Rita Gigliotti; Guido Pastore; Bruno De Bernardi
Journal:  J Clin Oncol       Date:  2010-03-29       Impact factor: 44.544

3.  Expression of ecto-5'-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma.

Authors:  Rafal Sadej; Jozef Spychala; Andrzej C Skladanowski
Journal:  Melanoma Res       Date:  2006-06       Impact factor: 3.599

4.  MYCN Amplification in Neuroblastoma: a Paradigm for the Clinical Use of an Oncogene.

Authors:  Manfred Schwab
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

5.  Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression.

Authors:  Asish K Ghosh; Charla R Secreto; Traci R Knox; Wei Ding; Debabrata Mukhopadhyay; Neil E Kay
Journal:  Blood       Date:  2009-12-17       Impact factor: 22.113

6.  The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.

Authors:  Tom Monclair; Garrett M Brodeur; Peter F Ambros; Hervé J Brisse; Giovanni Cecchetto; Keith Holmes; Michio Kaneko; Wendy B London; Katherine K Matthay; Jed G Nuchtern; Dietrich von Schweinitz; Thorsten Simon; Susan L Cohn; Andrew D J Pearson
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

7.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

Authors:  Susan L Cohn; Andrew D J Pearson; Wendy B London; Tom Monclair; Peter F Ambros; Garrett M Brodeur; Andreas Faldum; Barbara Hero; Tomoko Iehara; David Machin; Veronique Mosseri; Thorsten Simon; Alberto Garaventa; Victoria Castel; Katherine K Matthay
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

8.  Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry.

Authors:  Alberto Garaventa; Stefano Parodi; Bruno De Bernardi; Daniela Dau; Carla Manzitti; Massimo Conte; Fiorina Casale; Elisabetta Viscardi; Maurizio Bianchi; Paolo D'Angelo; Giulio Andrea Zanazzo; Roberto Luksch; Claudio Favre; Angela Tamburini; Riccardo Haupt
Journal:  Eur J Cancer       Date:  2009-07-16       Impact factor: 9.162

9.  Identification of ALK as a major familial neuroblastoma predisposition gene.

Authors:  Yaël P Mossé; Marci Laudenslager; Luca Longo; Kristina A Cole; Andrew Wood; Edward F Attiyeh; Michael J Laquaglia; Rachel Sennett; Jill E Lynch; Patrizia Perri; Geneviève Laureys; Frank Speleman; Cecilia Kim; Cuiping Hou; Hakon Hakonarson; Ali Torkamani; Nicholas J Schork; Garrett M Brodeur; Gian P Tonini; Eric Rappaport; Marcella Devoto; John M Maris
Journal:  Nature       Date:  2008-08-24       Impact factor: 49.962

Review 10.  Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles.

Authors:  Bence György; Tamás G Szabó; Mária Pásztói; Zsuzsanna Pál; Petra Misják; Borbála Aradi; Valéria László; Eva Pállinger; Erna Pap; Agnes Kittel; György Nagy; András Falus; Edit I Buzás
Journal:  Cell Mol Life Sci       Date:  2011-05-11       Impact factor: 9.261

View more
  11 in total

Review 1.  Targeting CD39 in cancer.

Authors:  Achim K Moesta; Xian-Yang Li; Mark J Smyth
Journal:  Nat Rev Immunol       Date:  2020-07-29       Impact factor: 53.106

Review 2.  ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain.

Authors:  Gennady G Yegutkin; Detlev Boison
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

Review 3.  Adenosine Metabolism: Emerging Concepts for Cancer Therapy.

Authors:  Detlev Boison; Gennady G Yegutkin
Journal:  Cancer Cell       Date:  2019-12-09       Impact factor: 31.743

4.  Detection of CD39 and a Highly Glycosylated Isoform of Soluble CD73 in the Plasma of Patients with Cervical Cancer: Correlation with Disease Progression.

Authors:  Ricardo Muñóz-Godínez; María de Lourdes Mora-García; Benny Weiss-Steider; Juan José Montesinos-Montesinos; Adriana Del Carmen Aguilar-Lemarroy; Rosario García-Rocha; Jorge Hernández-Montes; Christian Azucena Don-López; Luis Roberto Ávila-Ibarra; Daniela Berenice Torres-Pineda; Gabriela Molina-Castillo; Rommel Chacón-Salinas; Luis Vallejo-Castillo; Sonia Mayra Pérez-Tapia; Alberto Monroy-García
Journal:  Mediators Inflamm       Date:  2020-12-07       Impact factor: 4.711

Review 5.  Mechanisms, Diagnosis and Treatment of Bone Metastases.

Authors:  Jozef Ban; Valerie Fock; Dave N T Aryee; Heinrich Kovar
Journal:  Cells       Date:  2021-10-29       Impact factor: 6.600

Review 6.  Bone Marrow Environment in Metastatic Neuroblastoma.

Authors:  Chiara Brignole; Fabio Pastorino; Patrizia Perri; Loredana Amoroso; Veronica Bensa; Enzo Calarco; Mirco Ponzoni; Maria Valeria Corrias
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

Review 7.  CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies.

Authors:  Fabio Morandi; Irma Airoldi; Danilo Marimpietri; Cristiano Bracci; Angelo Corso Faini; Roberto Gramignoli
Journal:  Cells       Date:  2019-11-27       Impact factor: 6.600

Review 8.  On the mechanism of anti-CD39 immune checkpoint therapy.

Authors:  David Allard; Bertrand Allard; John Stagg
Journal:  J Immunother Cancer       Date:  2020-02       Impact factor: 13.751

9.  Host CD39 Deficiency Affects Radiation-Induced Tumor Growth Delay and Aggravates Radiation-Induced Normal Tissue Toxicity.

Authors:  Alina V Meyer; Diana Klein; Simone de Leve; Klaudia Szymonowicz; Martin Stuschke; Simon C Robson; Verena Jendrossek; Florian Wirsdörfer
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

10.  Human Amnion Epithelial Cells Impair T Cell Proliferation: The Role of HLA-G and HLA-E Molecules.

Authors:  Fabio Morandi; Danilo Marimpietri; Andre Görgens; Alessia Gallo; Raghuraman Chittor Srinivasan; Samir El-Andaloussi; Roberto Gramignoli
Journal:  Cells       Date:  2020-09-19       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.